ASCL1 and small cell lung carcinoma: SCLC transcription factors coexist intratumorally and undergo phenotypic switching under microenvironmental regulation—e.g., chemotherapy or ASCL1-targeted therapy enriches NEUROD1/POU2F3-positive cells, causing drug resistance and recurrence.